NO934334L - Vannuopplöselige manganpartikler som magnetisk resonans-kontrastforbedrende midler - Google Patents

Vannuopplöselige manganpartikler som magnetisk resonans-kontrastforbedrende midler

Info

Publication number
NO934334L
NO934334L NO934334A NO934334A NO934334L NO 934334 L NO934334 L NO 934334L NO 934334 A NO934334 A NO 934334A NO 934334 A NO934334 A NO 934334A NO 934334 L NO934334 L NO 934334L
Authority
NO
Norway
Prior art keywords
magnetic resonance
water
manganese
particles
soluble manganese
Prior art date
Application number
NO934334A
Other languages
English (en)
Other versions
NO934334D0 (no
Inventor
Wolfgang H H Gunther
Piotr H Karpinski
Kenneth E Kellar
Elaine Liversidge
Gregory L Mcintire
Barbara Vanorman
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of NO934334D0 publication Critical patent/NO934334D0/no
Publication of NO934334L publication Critical patent/NO934334L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

Magnetisk resonans-avbildnlngspreparat for avbildning av et organ som er rikt på mitokondrier, omfattende partikler av et vesentlig uoppløsellg mangansalt. Det beskrives også en fremgangsmåte for fremstilling av preparatet, som fordelaktig også Inneholder et overflateaktlvt middel, og denne fremgangsmåten omfatter anbringelse av en mangankilde i kontakt med en motionkilde i en tidsperiode og under betingelser som er tilstrekkelige til dannelse av nevnte uoppløselige mangansalt. Organet som er rikt på mitokondrier er fortrinnsvis leveren, partiklene er vesentlige ikke- magnetiske, idet en foretrukket partikkelstørre er mindre enn ca. 10 >jm og det uoppløselige mangansaltet velges fortrinnsvis fra gruppen bestående av manganfos- fat og mangankarbonat. Videre beskrives en diagnosemetode omfattende admini- strasjon til et pattedyr av en kontrasteffektlv mengde av et preparat av partiklene.
NO934334A 1992-12-17 1993-11-30 Vannuopplöselige manganpartikler som magnetisk resonans-kontrastforbedrende midler NO934334L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,893 US5401492A (en) 1992-12-17 1992-12-17 Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents

Publications (2)

Publication Number Publication Date
NO934334D0 NO934334D0 (no) 1993-11-30
NO934334L true NO934334L (no) 1994-06-20

Family

ID=25537695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934334A NO934334L (no) 1992-12-17 1993-11-30 Vannuopplöselige manganpartikler som magnetisk resonans-kontrastforbedrende midler

Country Status (15)

Country Link
US (1) US5401492A (no)
EP (1) EP0605908A3 (no)
JP (1) JPH06199703A (no)
KR (1) KR940013538A (no)
CN (1) CN1102348A (no)
AU (1) AU4885093A (no)
CA (1) CA2107695A1 (no)
CZ (1) CZ265093A3 (no)
FI (1) FI935309A (no)
HU (1) HUT65884A (no)
IL (1) IL107816A0 (no)
MX (1) MX9306625A (no)
NO (1) NO934334L (no)
NZ (1) NZ248812A (no)
SK (1) SK142693A3 (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
GB9619758D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US5980863A (en) 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7459283B2 (en) * 2002-02-04 2008-12-02 Elan Pharma International Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1401401B1 (en) * 2001-06-22 2005-03-30 Marie Lindner Method for high through put screening using a small scale mill or microfluidics
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4464129B2 (ja) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル，リミティド ナノ粒子インスリン製剤
ATE371442T1 (de) * 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003082213A2 (en) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
DK1494649T3 (da) 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP1503737B1 (en) * 2002-05-06 2009-01-07 Elan Pharma International Limited Nanoparticulate nystatin formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JP4878839B2 (ja) * 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
US20040156895A1 (en) * 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
JP4614281B2 (ja) * 2002-12-16 2011-01-19 ジーイー・ヘルスケア・アクスイェ・セルスカプ 磁気共鳴撮像方法並びに該方法に用いられる化合物
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
DE602004018150D1 (de) * 2003-08-08 2009-01-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US7419654B2 (en) * 2004-10-08 2008-09-02 Mrinal K. Dewanjee Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물
BRPI0609700A2 (pt) * 2005-03-23 2010-04-20 Elan Pharma Int Ltd formulações de corticosteróide nanoparticulado e antihistamina
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
WO2007086914A2 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
JP2008542397A (ja) * 2005-06-03 2008-11-27 エラン ファーマ インターナショナル リミテッド ナノ粒子メシル酸イマチニブ製剤
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
KR20090015994A (ko) * 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 나노입자형 포사코나졸 제제
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EA201790844A1 (ru) * 2017-05-15 2018-11-30 Деркач, Олег Вадимович Контрастное средство на основе аморфных или аморфно-кристаллических наночастиц оксидов или гидроксидов марганца для мрт исследований мозга

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
GB2012162B (en) * 1977-11-24 1982-08-11 Mccollester Duncan Lee Composition for use in the immunotherapy of neoplastic disease
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
CA1182748A (en) * 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS60221043A (ja) * 1984-04-18 1985-11-05 Toyo Jozo Co Ltd 飼料用糖ブロツクおよびそれを用いる飼育法
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
FR2596399B1 (fr) * 1986-03-28 1988-09-02 Univ Rennes Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament
US4889931A (en) * 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5077037A (en) * 1990-08-03 1991-12-31 Mallinckrodt Medical, Inc. Novel compositions for magnetic resonance imaging
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5344640A (en) * 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging

Also Published As

Publication number Publication date
JPH06199703A (ja) 1994-07-19
EP0605908A2 (en) 1994-07-13
NO934334D0 (no) 1993-11-30
CN1102348A (zh) 1995-05-10
FI935309A (fi) 1994-06-18
IL107816A0 (en) 1994-04-12
HUT65884A (en) 1994-07-28
KR940013538A (ko) 1994-07-15
EP0605908A3 (en) 1994-08-17
NZ248812A (en) 1995-11-27
CZ265093A3 (en) 1994-08-17
FI935309A0 (fi) 1993-11-29
SK142693A3 (en) 1994-10-05
HU9303489D0 (en) 1994-04-28
CA2107695A1 (en) 1994-06-18
MX9306625A (es) 1994-06-30
US5401492A (en) 1995-03-28
AU4885093A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
NO934334L (no) Vannuopplöselige manganpartikler som magnetisk resonans-kontrastforbedrende midler
CA2268324A1 (en) Administrable compositions and methods for magnetic resonance imaging
NO853075L (no) Fremgangsmaate for fremstilling av s-adenosyl-l-metionin (sam) salter.
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
SE8603582L (sv) Komposition innehallande l-dopa
NO20013154L (no) "Blood-pool"-midler for kjernemagnetisk resonans diagnostikk
CA2000112A1 (en) Iron containing preparation for nmr imaging and nmr imaging method using the same
CA2119345A1 (en) Methods for the In Vivo Measurement of the Concentration of NMR-Detectable Xenobiotic Compounds
ATE123955T1 (de) Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben.
WO2001080715A3 (en) Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
CA2016470A1 (en) Pharmaceutical preparation and method of treatment for liver dysfunction
Jans et al. Pathways for the synthesis of sorbitol from 13C‐labeled hexoses, pentose, and glycerol in renal papillary tissue
CA2208714A1 (en) Bone mass anabolic composition comprising olpadronate
Fukushima et al. L-Ascorbic acid amplification of bladder carcinogenesis promotion by K2CO3
DK0617027T3 (da) N-benzylpiperazinforbindelser, fremgangsmåde til fremstilling heraf og sammensætninger indeholdende forbindelserne
GB1356873A (en) Fungicidal compositions and their use
Pery-Man et al. Hydroxocobalamin vs cobalt toxicity on rat cardiac and diaphragmatic muscles
TR21596A (tr) Fungisid madde olarak yeni azolil-fenoksi-tetrahidrofuran-2-iliden metanlar
Vora et al. The effect of additives on red cell 2, 3 diphosphoglycerate levels in CPDA preservatives
JPS57146596A (en) Testing method of decarboxylating ability of microorganism by impedance method
JPS5340742A (en) Prostagilandin analogues, their preparation and medical composition containing the same as active constituents
EP0476156A4 (en) Solid oral preparation containing catechol compound
JPS52108088A (en) Preparation of monohydroxycarboxylic acid using microbials
JPS643106A (en) Mildewproofing agent
Worthington et al. Dibutyryl cyclic guanosine monophosphate elevates bovine endothelial cell thromboxane production without affecting prostacyclin metabolism